Janiczek Wealth Management LLC Sells 1,790 Shares of Johnson & Johnson (NYSE:JNJ)

Janiczek Wealth Management LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 26.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,858 shares of the company’s stock after selling 1,790 shares during the quarter. Janiczek Wealth Management LLC’s holdings in Johnson & Johnson were worth $761,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Cerity Partners LLC increased its stake in Johnson & Johnson by 75.7% during the fourth quarter. Cerity Partners LLC now owns 1,599,219 shares of the company’s stock worth $250,662,000 after acquiring an additional 688,955 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC increased its stake in Johnson & Johnson by 2.4% during the fourth quarter. Franklin Parlapiano Turner & Welch LLC now owns 46,861 shares of the company’s stock worth $7,345,000 after acquiring an additional 1,113 shares during the last quarter. Harbor Investment Advisory LLC grew its stake in shares of Johnson & Johnson by 2.4% during the fourth quarter. Harbor Investment Advisory LLC now owns 47,947 shares of the company’s stock valued at $7,515,000 after buying an additional 1,116 shares during the last quarter. Custom Index Systems LLC bought a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $433,000. Finally, Aspiriant LLC grew its stake in shares of Johnson & Johnson by 0.8% during the fourth quarter. Aspiriant LLC now owns 22,978 shares of the company’s stock valued at $3,602,000 after buying an additional 177 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 2.1 %

Johnson & Johnson stock opened at $144.45 on Wednesday. The business has a fifty day moving average of $156.80 and a two-hundred day moving average of $155.82. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The firm has a market cap of $348.09 billion, a P/E ratio of 10.46, a P/E/G ratio of 2.48 and a beta of 0.53. Johnson & Johnson has a twelve month low of $143.39 and a twelve month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. Johnson & Johnson’s revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.68 earnings per share. On average, analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. The ex-dividend date is Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a yield of 3.43%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is currently 34.47%.

Insider Activity

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on JNJ. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Monday. Raymond James upped their target price on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Morgan Stanley cut their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 28th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $177.31.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.